Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F21%3A10432369" target="_blank" >RIV/00216208:11150/21:10432369 - isvavai.cz</a>
Alternative codes found
RIV/00159816:_____/21:00074680 RIV/00064190:_____/21:N0000036 RIV/00843989:_____/21:E0109189 RIV/00216208:11110/21:10432369 and 5 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=vsgrQbBfFy" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=vsgrQbBfFy</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/invivo.12593" target="_blank" >10.21873/invivo.12593</a>
Alternative languages
Result language
angličtina
Original language name
Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
Original language description
Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. Patients and Methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pretreated with everolimus. Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
In Vivo
ISSN
0258-851X
e-ISSN
—
Volume of the periodical
35
Issue of the periodical within the volume
5
Country of publishing house
GR - GREECE
Number of pages
10
Pages from-to
2981-2990
UT code for WoS article
000686122800008
EID of the result in the Scopus database
2-s2.0-85113879329